Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a biologic drug calm the gut in ulcerative colitis? a Real-World trial seeks answers

NCT ID NCT07726888

Not yet recruiting Disease control Sponsor: Second Affiliated Hospital of Wenzhou Medical University Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This study is testing whether guselkumab, a biologic drug, can help people with moderate-to-severe ulcerative colitis achieve remission. Participants receive IV infusions followed by maintenance injections. The trial tracks clinical, endoscopic, and histological healing over 48 weeks in a real-world setting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
guselkumab, a biologic drug given by IV and then by injection
What this could lead to
If successful, this could offer a new treatment option for people with moderate-to-severe ulcerative colitis who have not responded to other therapies.
What could go wrong
This is a single-group, real-world study with no placebo comparison, so results may be less definitive. Side effects of guselkumab include infection risk and allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GUSELKUMAB are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GUSELKUMAB ULCERATIVE COLITIS (DISORDER)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Second Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, 325026, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.